| 1 | 三氧化二砷对慢性粒细胞白血病细胞系的作用(英文)显示文摘本研究探讨三氧化二砷 (As2 O3)对两种慢性粒细胞白血病 (CML)细胞系有无作用及作用机制。实验选用了两种不同的CML细胞系KU81 2和MEG 0 1及两种其它白血病细胞系U937和PL2 1 ,加入不同浓度的As2 O3(0 .2 ,2和 1 0 μmol/L) ,在不同时间计数活细胞数 ,观察细胞形态 ,并以TUNEL法和DNA凝胶电泳检测细胞有无凋亡的发生 ;同时检测 0 .2 μmol/LAs2 O3作用时细胞表面CD34 ,CD1 3 ,CD33 ,CD1 9,CD1 1b ,CD1 4和CD7的变化 ,并通过RT PCR检测细胞bcr abl水平及caspase 3的变化。研究结果发现 ,不同浓度的As2 O3对 4种细胞系的作用不同 ,1 0 μmol/L时 4种细胞系均会发生细胞凋亡 ,2 μmol/L时则仅CML细胞系KU81 2和MEG 0 1会产生凋亡 ,0 .2μmol/L时 4种细胞系均不发生凋亡。在培养 2 4小时后 ,4种细胞系表面的CD34 ,CD1 3 ,CD33 ,CD1 9,CD1 1b ,CD1 4和CD7等均无明显改变。RT PCR检测bcr abl的水平发现在 2种CML细胞系中无明显改变 ,其caspase 3的活性较对照细胞均有所增加。结论 :As2 O3在较高浓度下可诱导 4种白血病细胞系产生凋亡 ,在 2 μmol/L仅可诱导CML来源的两种细胞系产生凋亡 ,CML细胞系对As2 O3较其它两种细胞系敏感 ,其作用机制与caspase | 景红梅 Shimizu Yukihiro 克晓燕 Kashii Yoshiro Watanabe Akiharu | 2002 | 中国实验血液学杂志2002，10，5： | 3 |
| 3 | Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma显示文摘BACKGROUND Hepatocellular carcinoma(HCC)in hepatitis C virus(HCV)-infected patients has a high risk of recurrence.Although eradication of HCV is expected to reduce this risk,the risk in patients with a history of HCC may be high after treatment with direct-acting antivirals(DAAs).AIM To determine the risk factors for HCC recurrence in patients with HCV and a history of HCC.METHODS The risk of HCC recurrence in patients with a history of HCC and/or of HCC occurrence in patients without a history of HCC after DAA therapy was retrospectively analyzed in 311 HCV patients treated at our institution and several neighboring hospitals.The frequency and predictors of HCC recurrence/occurrence after DAA treatment were included in these analyses.The clinical course of HCC before and after DAA treatment was also evaluated.RESULTS HCV patients with a history of HCC were older and had greater progression of liver fibrosis and diabetes than patients without a history of HCC.Median recurrence-free survival(RFS)was 1092 d in patients with a history of HCC,and post-DAA HCC recurrence/occurrence was observed in 29 patients(53.7%)with and 5(1.9%)without a history of HCC over 6 years(P<0.001).RFS in patients with a history of HCC did not differ significantly before and after DAA treatment.The frequency of HCC recurrence/occurrence in patients with a history of HCC was lower after than before DAA treatment.Multivariate analysis showed that the incidence rate of HCC recurrence/occurrence before DAA treatment was the only independent predictor of HCC recurrence/occurrence after DAA treatment.Liver function was well preserved and clinical course was good in patients with HCC recurrence/occurrence after DAA therapy.CONCLUSION DAA therapy in patients infected with HCV is also effective in patients with a history of HCC.Curative treatment for HCC is desirable before DAA therapy.The frequency of HCC recurrence/occurrence before DAA therapy was associated with a significantly increased risk of HCC recurrence after DAA therapy.Careful observation after DAA therapy is required in patients with a history of HCC. | Kazuto Tajiri Hiroyuki Ito Kengo Kawai Yoshiro Kashii Yuka Hayashi Aiko Murayama Masami Minemura Terumi Takahara Yukihiro Shimizu Ichiro Yasuda | 2022 | World Journal of Hepatology2022，14，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员